Dynavax Technologies reported $32.04M in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US USD 3.3B 174M
Adma Biologics ADMA:US USD 17.75M 1.86M
Agenus AGEN:US USD 18.1M 809K
Amgen AMGN:US USD 1.29B 40M
AstraZeneca AZN:LN USD 3.35B 280M
Astrazeneca AZN:US USD 3.35B 280M
Biogen BIIB:US USD 563.3M 9.3M
Biomarin Pharmaceutical BMRN:US USD 216.82M 19.98M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Chimerix CMRX:US USD 5.31M 527K
Dynavax Technologies DVAX:US USD 32.04M 3.69M
Gilead Sciences GILD:US USD 1.21B 144M
Glaxosmithkline GSK:US GBP 1.97B 13M
Idera Pharmaceuticals IDRA:US USD 2.27M 391K
Merk MRK:US USD 2.47B 13M
Minerva Neurosciences NERV:US USD 2.84M 6.57K
Nektar Therapeutics NKTR:US USD 22.53M 1.09M
Neurocrine Biosciences NBIX:US USD 186.3M 3.5M
Novartis NOVN:VX USD 3.4B 185M
Pfizer PFE:US USD 3.54B 345M
Regeneron Pharmaceuticals REGN:US USD 529.1M 52.8M
Roche Holding ROG:VX 5.64B 899M
Sarepta Therapeutics SRPT:US USD 104.79M 49.53M
Tg Therapeutics TGTX:US USD 14.25M 1.62M
Vertex Pharmaceuticals VRTX:US USD 246.8M 31.5M